Peningkatan Aktivitas Hepatoprotektor Ekstrak Meniran Melalui Rekayasa Nanoteknologi Dengan Platform Self-nanoemulsifying Drug Delivery System (Snedds)
Abstract
Meniran (phyllanthus niruri) has been proven to have pharmacological activity as a hepatoprotector. The formulation of meniran extract into a self-nano emulsifying drug delivery system (SNEDDS) is because meniran extract has low solubility so its bioavailability is also low. Thus, this research aims to develop and characterize the SNEDDS formulation of meniran extract so that solubility. dissolution and bioavailability can be increased and to test the hepatoprotective activity of SNEDDS meniran extract. The SNEDDS formulation method begins with preformalation and SNEDDS meniran formulation followed by characterization of the formala with the test parameters percent transmittance, particle size, droplet distribution, zeta potential, stability tests (thermodynamic stability test, robustness test, accelerated stability test), FTIR, SEM, TEM, and bepatoprotective activity test. The hepatoprotective activity test uses in vivo methods by observing the enzyme activity of ALT. AST, and histopathological tests. Analysis of the results of the bepatoprotective activity test used statistical testing by comparing levels berveen groups with a confidence level of 95% (p<0.005). The optimal formula for meniran extract SNEDDS consists of a combination of labras (40%),ween 80 (40%), and propylene glycol (20%), with a drug loading value of memiran extract of 16.67%. The characterization values obtained were percent transmittance of 85.6+0.0%, particle size of 25.01.31 em with a polydisperson index of 0.48 0.1, and zeta potential of -33.37 a 0. 91mV Thermodynamic stability test shows that there is no phase separation in mura SNEDDS Rotsustness tests showed that the particle size, percent transmittance, and zota potential were stable at various dilution concentrations, An accelerated stability test for 3 months showed that there were no significant differences (p0.05) se transmittance, particle size and acta potential. SEM and TUM observations show that the morphology of SNEDDS meniran is spherical shape. The results of the ALT and AST enzyme activity were then analyzed using the 1-test, tukey test, bro-way and raka walis man whutney statistical tests with a confidence level of 95% The SNEDOS meniran ueatment group with a one of 100mg/Agfw was the optimal dose based on the ability to suppress the activity of the ALT and AST enzymes she gring high dines of PCT and when compared with the normal group, showed no significant difference (p>0.05). In addition, histopathological tests in this group showed that there was no incidence of excronis after high dose PCT administration based on METAVIR scoring
Collections
- Pharmacy [1481]